Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review

[1] D’Amico G(1987)The commonest glomerulonephritis in the world: IgA nephropathy Q J Med 64 709-727

[2] Levy M(1988)Worldwide perspective of IgA nephropathy Am J Kidney Dis 12 340-347

[3] Berger J(1997)Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases Am J Kidney Dis 29 526-532

[4] Koyama A(2000)Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors Am J Kidney Dis 36 227-237

[5] Igarashi M(2002)IgA nephropathy N Engl J Med 347 738-748

[6] Kobayashi M(2007)Remission of proteinuria improves prognosis in IgA nephropathy J Am Soc Nephrol 18 3177-3183

[7] D’Amico G(2009)A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study Nephrol Dial Transplant 24 3068-3074

[8] Donadio JV(2011)Predicting the risk for dialysis or death in IgA nephropathy J Am Soc Nephrol 22 752-761

[9] Grande JP(2005)Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis N Engl J Med 353 2219-2228

[10] Reich HN(2006)Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy J Nephrol 19 465-472

[1] D’Amico G(1987)The commonest glomerulonephritis in the world: IgA nephropathy Q J Med 64 709-727

[2] Levy M(1988)Worldwide perspective of IgA nephropathy Am J Kidney Dis 12 340-347

[3] Berger J(1997)Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases Am J Kidney Dis 29 526-532

[4] Koyama A(2000)Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors Am J Kidney Dis 36 227-237

[5] Igarashi M(2002)IgA nephropathy N Engl J Med 347 738-748

[6] Kobayashi M(2007)Remission of proteinuria improves prognosis in IgA nephropathy J Am Soc Nephrol 18 3177-3183

[7] D’Amico G(2009)A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study Nephrol Dial Transplant 24 3068-3074

[8] Donadio JV(2011)Predicting the risk for dialysis or death in IgA nephropathy J Am Soc Nephrol 22 752-761

[9] Grande JP(2005)Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis N Engl J Med 353 2219-2228

[10] Reich HN(2006)Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy J Nephrol 19 465-472